Sai Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma CDMO

May 15, 2026
Posted by: Kunal Singla
Category: News

Sai Life Sciences Q4 FY26 results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT rose 18.09% YoY to Rs 104.24 crore on revenue of Rs 602.14 crore (+3.91% YoY). FY26 annual PAT Rs 348.91 crore (+105% YoY); FY26 revenue Rs 2,192.49 crore (+29.38%). CRDMO business momentum sustained with CDMO at 65% and CRO at 35% of revenue mix. 9M FY26 PAT was Rs 245 crore (+199% YoY). Capital expenditure of Rs 633 crore in FY26 to expand manufacturing and R&D capacity. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Sai Life Sciences Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 104.24 crore	up 18.09% YoY from Rs 88.27 crore in Q4 FY25
Revenue from Operations	Rs 602.14 crore	Q4 FY26
Ticker	SAILIFE	Sector: Pharma CDMO

Screen the best stocks on the Univest Screener.

Sai Life Sciences Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company is an innovator-focused CRDMO (Contract Research, Development and Manufacturing Organization) with revenue estimation of Rs 370-40 Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Sai Life Sciences FY27 Outlook

Post Sai Life Sciences, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharma CDMO space. The Sai Life Sciences results demonstrate the company’s execution capabilities. Track Sai Life Sciences updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Sai Life Sciences Q4 FY26 Results

What is Sai Life Sciences Q4 FY26 PAT?

Ans. Sai Life Sciences Q4 FY26 PAT of Rs 104.24 crore (results declared May 14, 2026). Q4 FY26 PAT rose 18.09% YoY to Rs 104.24 crore on revenue of Rs 602.14 crore (+3.91% YoY). FY26 annual PAT Rs 348.91 crore (+105% YoY); FY26 revenue R.

When did Sai Life Sciences announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Sai Life Sciences?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharma CDMO sector. Track live updates on the Univest Screener.

Where can I track Sai Life Sciences Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.